AFT Pharmaceuticals Limited

CHIA:AFP Stock Report

Market Cap: AU$274.5m

AFT Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

AFT Pharmaceuticals has been growing earnings at an average annual rate of 9.7%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 15.6% per year. AFT Pharmaceuticals's return on equity is 13.6%, and it has net margins of 5.8%.

Key information

9.7%

Earnings growth rate

9.2%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate15.6%
Return on equity13.6%
Net Margin5.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How AFT Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:AFP Revenue, expenses and earnings (NZD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2419912628
30 Jun 2419714607
31 Mar 2419516586
31 Dec 2318513576
30 Sep 2317511565
30 Jun 2316611534
31 Mar 2315711494
31 Dec 2214914464
30 Sep 2214117424
30 Jun 2213518404
31 Mar 2213020384
31 Dec 2112515383
30 Sep 2112011393
30 Jun 211169382
31 Mar 211138372
31 Dec 201105361
30 Sep 201073360
30 Jun 201077370
31 Mar 2010612370
31 Dec 1910011360
30 Sep 199411351
30 Jun 19894351
31 Mar 1985-3351
31 Dec 1884-7382
30 Sep 1883-11404
30 Jun 1882-12395
31 Mar 1881-14397
31 Dec 1779-14378
30 Sep 1776-143410
30 Jun 1773-163410
31 Mar 1769-18349
31 Dec 1667-18338
30 Sep 1664-18328
30 Jun 1664-16307
31 Mar 1664-13296
31 Dec 1563-13275
30 Sep 1562-13264
30 Jun 1559-13254
31 Mar 1556-13245
31 Mar 1449-1162

Quality Earnings: AFP has high quality earnings.

Growing Profit Margin: AFP's current net profit margins (5.8%) are lower than last year (6.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AFP's earnings have grown by 9.7% per year over the past 5 years.

Accelerating Growth: AFP's earnings growth over the past year (6.3%) is below its 5-year average (9.7% per year).

Earnings vs Industry: AFP earnings growth over the past year (6.3%) did not outperform the Pharmaceuticals industry 26.6%.


Return on Equity

High ROE: AFP's Return on Equity (13.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 14:03
End of Day Share Price 2024/12/13 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AFT Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Jack CrowleyCredit Suisse
Soo RomanoffEdison Investment Research